BOOST Pharma
- | Biotech or pharma, therapeutic R&D
BOOST Pharma is developing a first-in-class therapy to treat Osteogenesis Imperfecta, a rare genetic disease. The Company has established a strong clinical safety data base. Recent Phase I/II showed excellent safety and high efficacy (reduction of bone fractures) in children born with OI.
Positive top-line clinical results were announced in September 2024.
FDA fully accepted in October 2024 our proposal for pivotal Ph III trial.
Address
CopenhagenDenmark
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}